TY - JOUR
T1 - Galanin expression within the basal forebrain in Alzheimer's disease
T2 - Comments on therapeutic potential
AU - Mufson, Elliott J.
AU - Kahl, Ulrika
AU - Bowser, Robert
AU - Mash, Deborah C.
AU - Kordower, Jeffrey H.
AU - Deecher, Darlene C.
PY - 1998
Y1 - 1998
N2 - The inhibitory neuropeptide galanin has widespread distribution throughout the central nervous system. Studies indicate that galanin modulates cognition by regulating cholinergic basal forebrain (CBF) neuron function. The chemoanatomic organization of galanin within the mammalian CBF differs across species. In monkeys, all CBF neurons coexpress galanin, whereas in apes and humans galanin is found within a separate population of interneurons that are in close apposition to the CBF perikarya. Pharmacologic investigations revealed a low and high affinity galanin receptor within the basal forebrain in humans. In vitro autoradiographic investigations of the primate brain indicate that galanin receptors are concentrated within the anterior subfields of the CBF as well as the bed nucleus of the stria terminalis, amygdala, and entorhinal cortex. Galaninergic fibers hyperinnervate remaining CBF neurons in Alzheimer's disease. Because galanin inhibits the release of acetylcholine in the hippocampus, it has been suggested that the overexpression of galanin in Alzheimer's disease may downregulate the production of acetylcholine within CBF perikarya, further exacerbating cholinergic cellular dysfunction in this disorder. These observations suggest that the development of a potent galanin antagonist would be a useful step towards the successful pharmacologic treatment of Alzheimer's disease.
AB - The inhibitory neuropeptide galanin has widespread distribution throughout the central nervous system. Studies indicate that galanin modulates cognition by regulating cholinergic basal forebrain (CBF) neuron function. The chemoanatomic organization of galanin within the mammalian CBF differs across species. In monkeys, all CBF neurons coexpress galanin, whereas in apes and humans galanin is found within a separate population of interneurons that are in close apposition to the CBF perikarya. Pharmacologic investigations revealed a low and high affinity galanin receptor within the basal forebrain in humans. In vitro autoradiographic investigations of the primate brain indicate that galanin receptors are concentrated within the anterior subfields of the CBF as well as the bed nucleus of the stria terminalis, amygdala, and entorhinal cortex. Galaninergic fibers hyperinnervate remaining CBF neurons in Alzheimer's disease. Because galanin inhibits the release of acetylcholine in the hippocampus, it has been suggested that the overexpression of galanin in Alzheimer's disease may downregulate the production of acetylcholine within CBF perikarya, further exacerbating cholinergic cellular dysfunction in this disorder. These observations suggest that the development of a potent galanin antagonist would be a useful step towards the successful pharmacologic treatment of Alzheimer's disease.
UR - http://www.scopus.com/inward/record.url?scp=0032430457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032430457&partnerID=8YFLogxK
U2 - 10.1111/j.1749-6632.1998.tb10703.x
DO - 10.1111/j.1749-6632.1998.tb10703.x
M3 - Article
C2 - 9928179
AN - SCOPUS:0032430457
SN - 0077-8923
VL - 863
SP - 291
EP - 304
JO - Annals of the New York Academy of Sciences
JF - Annals of the New York Academy of Sciences
ER -